Clinical Trials

Dual PDE3/4 inhibitor AN01 improved lung function versus placebo in COPD patients already on bronchodilator therapy, with data presented at ERS 2026.

The Cambridge, Massachusetts biotech secured FDA acceptance of its Oxnimbi NDA with a PDUFA date of 28 February 2027, as it raised $221m in a

Assembly Biosciences will take a 40% share of US costs and profits for the GS-1179 helicase-primase inhibitor as a Phase 2 trial approaches.

BridgeBio Oncology Therapeutics posted new Phase 1 data showing its KRAS G12C inhibitor combo achieved a 75% response rate in inhibitor-experienced lung cancer patients.

The Seattle-based biotech will use proceeds to run its ILLUMINATE Phase 2 study of BCB-276 in diffuse intrinsic pontine glioma, a universally fatal

Dyne will present pooled Phase 1/2 data for z-basivarsen against a matched natural history cohort, with registrational topline results due Q1 2027.

The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9

Novartis has dosed its first Sjögren's disease patient with MRT-6160, triggering a $50m payment to Monte Rosa under the pair's $2.1bn

Pharvaris's CHAPTER-3 Phase 3 study of once-daily deucrictibant XR met all endpoints, with NDA submissions planned for the first half of 2027.

Phase 2 PHocus trial showed a 56.3% placebo-adjusted PVR reduction; Roivant has now initiated the Phase 3 PHrontier study in the same indication.

SPY003 met its primary endpoint in ulcerative colitis, giving Spyre positive Phase 2 monotherapy readouts for all three of its IBD combination components.

Vor Bio has fully enrolled its global Phase 3 gMG study and will initiate a sister trial in ocular myasthenia gravis, with topline data expected

The Nasdaq-listed oncology company has detailed patents covering APR-1051 and ATRN-119, with WEE1 protection potentially running to 2047.

Ascendis Pharma will share sentinel cohort data from its reACHin pivotal trial of navepegritide in infants under two at ESPE 2026.

BTT Medical Institute has launched a safety trial of its brain-guided hyperthermia system, citing a single ALS case report as the basis for development.

Del-desiran failed to improve hand myotonia in a 150-patient Phase III study, though secondary endpoints showed signs of clinical activity.

Phase 3 STEP Young data show 40.4% of children aged 6 to 11 treated with semaglutide dropped below the obesity BMI threshold after 68

The Belgian medtech has begun a 229-patient, five-year US real-world study of its Genio bilateral hypoglossal nerve stimulator, approved by the FDA

Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.

An injectable synthetic bone void filler from Biomimetic Innovations was used in a tibial plateau fracture repair at the University of Leeds, marking the start